Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells

Esophageal adenocarcinoma is a lethal malignancy which is increasing in incidence, and many patients receive chemotherapy as part of their treatment. We have previously demonstrated that esophageal adenocarcinoma-derived cell lines respond to treatment with estrogen receptor modulators, such as tamoxifen. Reports from breast cancer suggest that tamoxifen may attenuate the efficacy of other chemotherapeutic agents. We have therefore assessed the response of esophageal adenocarcinoma cell lines to tamoxifen therapy when given in combination with conventional agents.

Source: Surgical Oncology - May 26, 2016 Category: Surgery Authors: S.L. Due, D.I. Watson, I. Bastian, G.Q. Ding, O.A. Sukocheva, D.St.J. Astill, L. Vat, D.J. Hussey Source Type: research